EUVIMEDEUVIMED entdecken
Crossref

Effect of pretreatment vascular endothelial growth factor inhibitor use on the safety and efficacy of trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancer

Koshiro Fukuda, Hiroki Osumi, Akira Ooki, Daisaku Kamiimabeppu, Shohei Udagawa, Shota Fukuoka, Mariko Ogura, Takeru Wakatsuki, Keisho Chin, Mitsuhiro Fujishiro, Kensei Yamaguchi, Eiji Shinozaki

International Journal of Clinical Oncology · 2025

DOI: 10.1007/s10147-025-02831-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Clinical Oncology, 2025. Verfasst von Koshiro Fukuda und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterological Chemotherapy, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Trifluridine, Antineoplastic Combined Chemotherapy Protocols, Vascular Endothelial Growth Factor A. Die Arbeit nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The effect of vascular endothelial growth factor (VEGF) inhibitor pretreatment on clinical outcomes of trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV) in patients with metastatic colorectal cancer (mCRC) remains unclear. We aimed to investigate this effect. METHODS: Patients with mCRC treated with FTD/TPI plus BEV were retrospectively enrolled. Disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and adverse events (AEs) were compared. In total, 73, 50, and 33 patients were treated with fluorouracil+levofolinate calcium+irinotecan (FOLFIRI) plus BEV, ramucirumab, and aflibercept, respectively. RESULTS: The DCR and median PFS/OS did not significantly differ among the groups (DCR: 54.8% vs. 56.0% vs. 42.4%, P = 0.43; PFS: 3.9 vs. 4.6 vs. 3.7 months, P = 0.45; OS: 12.0 vs. 9.5 vs. 11.9 months, P = 0.28). The most common grade 3-4 AE was neutropenia. The incidence of grade 3-4 AEs did not significantly differ among the groups. The frequency of grade ≥2 proteinuria during FTD/TPI plus BEV treatment was significantly higher in patients with grade ≥2 proteinuria before FOLFIRI plus VEGF inhibitor use than in those without proteinuria. Multivariate analysis revealed poor performance status (ECOG PS) and liver metastasis as independent predictors of short PFS/OS (ECOG PS, PFS: P = 0.021, OS: P < 0.001; liver metastasis, PFS: P = 0.03, OS: P < 0.001) and grade 3-4 neutropenia in a month as a predictor of long PFS/OS (PFS: P = 0.047, OS: P = 0.03). CONCLUSION: Different pretreatment VEGF inhibitors did not affect the efficacy and safety of FTD/TPI plus BEV.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsTrifluridineAntineoplastic Combined Chemotherapy ProtocolsVascular Endothelial Growth Factor AHumansMaleBevacizumabFemaleMiddle AgedAgedPyrrolidinesThymineRetrospective StudiesAdultDrug CombinationsFluorouracilAntibodies, Monoclonal, HumanizedCamptothecinLeucovorinAged, 80 and overNeoplasm MetastasisRamucirumabProgression-Free SurvivalReceptors, Vascular Endothelial Growth Factor

Stichwörter der Autor:innen

AfliberceptBevacizumabNeutropeniaProteinuriaRamucirumabTrifluridine/tipiracil

Substanzen

TrifluridineBevacizumabPyrrolidinesThyminetrifluridine tipiracil drug combinationVascular Endothelial Growth Factor ADrug CombinationsFluorouracilAntibodies, Monoclonal, HumanizedCamptothecin

Autor:innen und Institutionen

  • Department of Gastroenterological Chemotherapy, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Department of Surgery, Kirishima Medical Center, Kagoshima, Japan.
  • Department of Gastroenterological Chemotherapy, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan. eiji.shinozaki@jfcr.or.jp.

Zitieren

APA

Fukuda, K., Osumi, H., Ooki, A., Kamiimabeppu, D., Udagawa, S., Fukuoka, S., Ogura, M., Wakatsuki, T., Chin, K., Fujishiro, M., Yamaguchi, K., & Shinozaki, E. (2025). Effect of pretreatment vascular endothelial growth factor inhibitor use on the safety and efficacy of trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancer. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-025-02831-0

Vancouver

Fukuda K, Osumi H, Ooki A, Kamiimabeppu D, Udagawa S, Fukuoka S, et al. Effect of pretreatment vascular endothelial growth factor inhibitor use on the safety and efficacy of trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancer. International Journal of Clinical Oncology. 2025. doi:10.1007/s10147-025-02831-0

BibTeX
@article{Fukuda2025,
  author = {Fukuda, Koshiro and Osumi, Hiroki and Ooki, Akira and Kamiimabeppu, Daisaku and Udagawa, Shohei and Fukuoka, Shota and Ogura, Mariko and Wakatsuki, Takeru and Chin, Keisho and Fujishiro, Mitsuhiro and Yamaguchi, Kensei and Shinozaki, Eiji},
  title = {Effect of pretreatment vascular endothelial growth factor inhibitor use on the safety and efficacy of trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancer},
  journal = {International Journal of Clinical Oncology},
  year = {2025},
  doi = {10.1007/s10147-025-02831-0}
}
Kostenlos starten →